News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Regulatory and legal
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Seres Therapeutics Inc (NASDAQ: MCRB) reported second-quarter earnings per share of $0.47, significantly surpassing the analyst estimate of -$2.30 by $2.77. The company also exceeded revenue expectations, bringing in $736K against a consensus estimate of $358K. Despite the strong earnings beat, the stock has …
Seres Therapeutics (MCRB) reported a net income of $4.6 million in Q2 2026, a significant improvement from a net loss of $19.9 million in the prior year, primarily due to a $25 million gain from the sale of its VOWST business. The company also …
Seres Therapeutics announced its second quarter 2026 financial results, highlighting positive topline data from its SER-155 trial for immune checkpoint inhibitor-related enterocolitis (irEC) and reporting 80% immunosuppressive-free clinical response at day 15. The company is actively seeking partners and capital to advance its SER-155 …
Seres Therapeutics Inc. reported a profit of $4.6 million, or 47 cents per share, in its second quarter. The drug developer's losses, when adjusted for non-recurring gains, were $1.50 per share. Revenue for the period was $736,000.
Seres Therapeutics Inc is projected to report an earnings loss of $2.18 per share. This information comes from an earnings preview provided by Refinitiv. The article focuses on the preliminary financial expectations for the company.
This article provides a technical analysis of Seres Therapeutics Inc (MCRB), highlighting its current price momentum score as 5.77 within the Biotechnology & Medical Research industry. It identifies the stock's support level at $3.41 and resistance level at $7.07, suggesting suitability for range-bound swing …
Seres Therapeutics, Inc. (MCRB) is projected to release its Q2'26 earnings on August 5th, with an estimated revenue of $179.00 thousand and an anticipated EPS of ($2.19) USD. The article provides historical revenue and EPS data alongside these estimates, noting past surprises in both …
This article provides a comprehensive stock analysis of Seres Therapeutics Inc (MCRB) by TradingKey, highlighting its relatively stable fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes very high institutional ownership and multiple "Buy" ratings from …
The article provides a historical overview of Seres Therapeutics Inc (MCRB) regarding its dividend payouts and stock splits. It states that the company has distributed $0.00 in dividends over the past five years and lists a future merger event with a 20:1 ratio scheduled …
This article provides an earnings forecast for Seres Therapeutics Inc (MCRB), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on two analysts, the stock has a "Buy" recommendation with an average target price of $21.00. The report also details …
This article provides a revenue breakdown for Seres Therapeutics Inc (MCRB), detailing its business segments, regional revenue, and profit contributions. As of the report, relevant data for FY2021-FY2025 have not been disclosed by the company. The only specific regional revenue figure provided is for …
This article provides a financial health analysis of Seres Therapeutics Inc (MCRB), indicating a current financial score of 5.80, which ranks 326 out of 386 in the Biotechnology & Medical Research industry. The company's financial status is described as weak with low operating efficiency. …
Seres Therapeutics presented a summary of their drug technology and pipeline at the H.C. Wainwright 4th Annual BioConnect Investor Conference. They highlighted their novel drug technology using bacterial consortia, leading to the first FDA-approved oral microbiome drug with an 88% sustained response for C. …
Search by ticker symbol or company name and select a result to open its chart.